China Resources Shuanghe announced that China Resources Zizhu Pharmaceutical, a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for propranolol hydrochloride injections issued by the State Drug Administration and approved the addition of 2ml:2mg specifications. The drug passed the consistent evaluation of the quality and efficacy of generic drugs. This drug is suitable for controlling ventricular rapid arrhythmias, labor-type angina pectoris, etc. As of the announcement date, the company has invested a total of 3.3384 million yuan in R&D. In 2025, the drug's sales revenue was 3.062 million yuan.

China Resources Shuanghe announced that China Resources Zizhu Pharmaceutical, a wholly-owned subsidiary of the company, received the “Drug Supplement Application Approval Notice” for propranolol hydrochloride injections issued by the State Drug Administration and approved the addition of 2ml:2mg specifications. The drug passed the consistent evaluation of the quality and efficacy of generic drugs. This drug is suitable for controlling ventricular rapid arrhythmias, labor-type angina pectoris, etc. As of the announcement date, the company has invested a total of 3.3384 million yuan in R&D. In 2025, the drug's sales revenue was 3.062 million yuan.